Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

June 27, 2012

Using the XS Toolbox to Optimize Strain Design and Development for Efficient Microbial GMP Production

Keynote Speaker for this Event:
  • Dr. Joachim Klein, Group Leader, Microbial R&D, Lonza Biopharmaceuticals,
    Learn More
  • Using the XS Toolbox to Optimize Strain Design and Development for Efficient Microbial GMP Production

    No single strain or vector is capable of being the best expression option for all types of biopharmaceuticals. Therefore, Lonza has assembled a collection of proprietary expression systems to address the diversity of microbially derived proteins. Our XS Technology™ Platform has shown expression levels in excess of 19 g/L.

    Scientists face many expression challenges including inclusion bodies, low expression levels, and product instability. Lonza has created a rationally designed experimental process to identify the best production choice for the product of interest. This unique toolbox of experimental options includes a selection of host organisms, plasmids, promoters, selection markers, signal sequences, translational initiation regions, and stabilizing elements. Following initial strain design, samples are immediately screened using a variety of analytical techniques including SDS PAGE, Western Blot, Dot Blot, ELISA Assays, biolayer interferometry and capillary electrophoresis. Depending on the host organism, final strain selection is achieved within 6 to 8 weeks, starting from synthesized gene through to final production strain.

    Case studies will be presented on use of the XS tool box to address common problems such as:

    • Low Productivity
    • Product-related impurities
    • Insolubility
    • Plasmid and Host Instability

    The Lonza XS System™ ultimately decreases the time of strain screening and design to enable the fast creation of a valuable production strain and efficient cGMP process.


    This webinar is designed for fermentation and expression specialists with a focus in the areas of cell culture and strain development.


    Dr. Joachim Klein, Group Leader, Microbial R&D, Lonza Biopharmaceuticals, Switzerland

    Dr. Klein has 20 years of experience in academia and industry in the fields of molecular biology and microbiology. He is responsible for strain development and strain characterization, covering the whole range of microbial expression hosts such as Gram-positive bacteria, Gram-negative bacteria, yeasts and filamentous fungi. Dr. Klein received his “pre-diploma” (B.S.) in Saarbrücken (Germany) and his diploma (M.S.) in Biology in Kaiserlautern (Germany). He received his Ph.D. in Molecular Biology from the University of Stuttgart (Germany) and completed his post-doctoral studies in Stuttgart. Prior to joining Lonza he spent 3 years as an Assistant Professor with the Institute of Industrial Genetics in Stuttgart engineering bacteria for the detection, degradation and conversion of toxic environmental compounds.


    For over 30 years, Lonza Custom Manufacturing has been helping emerging and established biotech and pharmaceutical companies improve and successfully advance their products to the next level. Whether for clinical or commercial supply, Lonza’s full set of development services, industry-leading manufacturing processes, and broad chemical and biotechnology platforms enable you to reach your clinical milestones earlier.

    For more information visit www.lonza.com

    For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email register@xtalks.com

    Copyright © 2016-2017 Honeycomb Worldwide Inc.